CEL-SCI Corp
CVM4.980USD
-0.520-9.45%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
26.50MMarket Cap
LossP/E TTM
More Details of CEL-SCI Corp Company
CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
CEL-SCI Corp Info
Ticker SymbolCVM
Company nameCEL-SCI Corp
IPO dateDec 08, 1983
CEOKersten (Geert R)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endDec 08
AddressSuite 802
CityVIENNA
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code22182
Phone17035069460
Websitehttps://cel-sci.com/
Ticker SymbolCVM
IPO dateDec 08, 1983
CEOKersten (Geert R)
Company Executives of CEL-SCI Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Geert R. Kersten, Esq.
Mr. Geert R. Kersten, Esq.
Chief Executive Officer, Chief Financial Officer, Treasurer, Director
Chief Executive Officer, Chief Financial Officer, Treasurer, Director
81.79K
+11.43%
Ms. Patricia B. Prichep
Ms. Patricia B. Prichep
Co-Chief Financial Officer, Chief Operating Officer, Corporate Secretary
Co-Chief Financial Officer, Chief Operating Officer, Corporate Secretary
11.21K
+4.34%
Dr. Eyal Talor, Ph.D.
Dr. Eyal Talor, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
5.81K
+4.69%
Mr. Robert Eugene (Bob) Watson
Mr. Robert Eugene (Bob) Watson
Independent Chairman of the Board
Independent Chairman of the Board
3.73K
+358.60%
Mr. Bruno Jean-Marie Baillavoine
Mr. Bruno Jean-Marie Baillavoine
Independent Director
Independent Director
199.00
--
Mr. John Cipriano
Mr. John Cipriano
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Mr. Mario Gobbo, Ph.D.
Mr. Mario Gobbo, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel H. Zimmerman, Ph.D.
Dr. Daniel H. Zimmerman, Ph.D.
Senior Vice President - Research, Cellular Immunology
Senior Vice President - Research, Cellular Immunology
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Geert R. Kersten, Esq.
Mr. Geert R. Kersten, Esq.
Chief Executive Officer, Chief Financial Officer, Treasurer, Director
Chief Executive Officer, Chief Financial Officer, Treasurer, Director
81.79K
+11.43%
Ms. Patricia B. Prichep
Ms. Patricia B. Prichep
Co-Chief Financial Officer, Chief Operating Officer, Corporate Secretary
Co-Chief Financial Officer, Chief Operating Officer, Corporate Secretary
11.21K
+4.34%
Dr. Eyal Talor, Ph.D.
Dr. Eyal Talor, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
5.81K
+4.69%
Mr. Robert Eugene (Bob) Watson
Mr. Robert Eugene (Bob) Watson
Independent Chairman of the Board
Independent Chairman of the Board
3.73K
+358.60%
Mr. Bruno Jean-Marie Baillavoine
Mr. Bruno Jean-Marie Baillavoine
Independent Director
Independent Director
199.00
--
Mr. John Cipriano
Mr. John Cipriano
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lincoln Alternative Strategies LLC
6.92%
The Vanguard Group, Inc.
3.65%
Commonwealth Financial Network
2.19%
BlackRock Institutional Trust Company, N.A.
1.70%
Kersten (Geert R)
1.02%
Other
84.52%
Shareholders
Shareholders
Proportion
Lincoln Alternative Strategies LLC
6.92%
The Vanguard Group, Inc.
3.65%
Commonwealth Financial Network
2.19%
BlackRock Institutional Trust Company, N.A.
1.70%
Kersten (Geert R)
1.02%
Other
84.52%
Shareholder Types
Shareholders
Proportion
Investment Advisor
8.33%
Corporation
6.92%
Investment Advisor/Hedge Fund
2.18%
Individual Investor
1.36%
Research Firm
0.54%
Hedge Fund
0.03%
Other
80.64%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
119
887.81K
8.30%
--
2025Q3
124
887.81K
8.34%
+389.09K
2025Q2
124
498.72K
7.08%
+233.20K
2025Q1
129
265.51K
10.75%
-35.82K
2024Q4
142
245.99K
10.93%
+34.78K
2024Q3
148
211.20K
13.20%
-9.43K
2024Q2
158
222.03K
15.91%
-38.34K
2024Q1
213
260.37K
16.32%
-33.20K
2023Q4
221
227.99K
16.02%
+38.70K
2023Q3
230
189.29K
17.54%
-2.23K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Lincoln Alternative Strategies LLC
555.00K
6.94%
+555.00K
--
Aug 27, 2025
The Vanguard Group, Inc.
183.21K
2.29%
+104.78K
+133.58%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
114.25K
1.43%
+88.15K
+337.80%
Jun 30, 2025
Kersten (Geert R)
73.41K
0.92%
+570.00
+0.78%
Sep 30, 2025
MAI Capital Management, LLC
64.93K
0.81%
+47.38K
+270.01%
Jun 30, 2025
Geode Capital Management, L.L.C.
25.92K
0.32%
+821.00
+3.27%
Jun 30, 2025
BofA Global Research (US)
40.98K
0.51%
+40.92K
+68201.67%
Jun 30, 2025
Osaic Holdings, Inc.
15.53K
0.19%
+5.89K
+61.17%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
May 19, 2025
Merger
30→1
Date
Type
Ratio
May 19, 2025
Merger
30→1
FAQs
Who are the top five shareholders of CEL-SCI Corp?
The top five shareholders of CEL-SCI Corp are:
Lincoln Alternative Strategies LLC holds 555.00K shares, accounting for 6.94% of the total shares.
The Vanguard Group, Inc. holds 183.21K shares, accounting for 2.29% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 114.25K shares, accounting for 1.43% of the total shares.
Kersten (Geert R) holds 73.41K shares, accounting for 0.92% of the total shares.
MAI Capital Management, LLC holds 64.93K shares, accounting for 0.81% of the total shares.
Lincoln Alternative Strategies LLC holds 555.00K shares, accounting for 6.94% of the total shares.
The Vanguard Group, Inc. holds 183.21K shares, accounting for 2.29% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 114.25K shares, accounting for 1.43% of the total shares.
Kersten (Geert R) holds 73.41K shares, accounting for 0.92% of the total shares.
MAI Capital Management, LLC holds 64.93K shares, accounting for 0.81% of the total shares.
What are the top three shareholder types of CEL-SCI Corp?
The top three shareholder types of CEL-SCI Corp are:
Lincoln Alternative Strategies LLC
The Vanguard Group, Inc.
Commonwealth Financial Network
Lincoln Alternative Strategies LLC
The Vanguard Group, Inc.
Commonwealth Financial Network
How many institutions hold shares of CEL-SCI Corp (CVM)?
As of 2025Q4, 119 institutions hold shares of CEL-SCI Corp, with a combined market value of approximately 887.81K, accounting for 8.30% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.04%.
What is the biggest source of revenue for CEL-SCI Corp?
In --, the -- business generated the highest revenue for CEL-SCI Corp, amounting to -- and accounting for --% of total revenue.
